Poking CD40 for cancer therapy, another example of the goldilocks effect

Cancer Biology and Therapy

Volumn 10, Issue 10, 2010, Pages 994-996

  Drabick, Joseph J ^a   Schell, Todd D ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

Cancer; CD154; CD40; Dendritic cell; Immunotherapy; Monoclonal antibody; T helper cell

Indexed keywords

CD40 ANTIGEN; CP 870893;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER THERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL TRIAL; HUMAN; IMMUNOTHERAPY; MELANOMA; TREATMENT RESPONSE; TUMOR IMMUNITY;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD40; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; REMISSION INDUCTION;

EID: 78549247887     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.10.10.13976     Document Type: Article

References (15)

1. Van Kooten C, Banchereau J. CD40-CD40 ligand. J Leukoc Biol 2000; 67:2-17.
2. Armitage RJ, Fanslow WC, Strockbine L, Sato TA, Clifford KN, Macduff BM, et al. Molecular and biological characterization of murine ligand for CD40. Nature 1992; 357:80-2.
3. French RR, Chan HT, Tutt AL, GLennie MJ. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat Med 1999; 5:774-9.
4. Vonderheide RH. Prospect of targeting the CD40 pathway for cancer therapy. Clin Cancer Res 2007; 13:1083-8.
5. Gladue R, Cole S, Donovan C, Paradis T, Alpert R, Natoli E, et al. In vivo efficacy of the CD40 agonist antibody CP-870,893 against a borad range of tumor types: impact of tumor CD40 expression, dendritic cells and chemotherapy. J Clin Oncol 2007; 25:876-83.
6. Van Mierlo GJ, den Boer AT, Medema JP, van der Voort EI, Fransen MF, Offringa R, et al. CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong cytotoxic T lymphocyte immunity. Proc Natl Acad Sci USA 2002; 99:5561-6.
7. Vonderheide RH, Flaherty KT, Khalil M, Stumacher MS, Bajor DL, Hutnick NA, et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clinic Oncol 2007; 25:876-83.
8. Ruter J, Antonia SJ, Burris HA, 3rd, Huhn RD, Vonderheide RH. Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced tumors. Cancer Biol Ther 2010; 10:983-93.
9. + T-cell loss and impairs secondary antitumor responses after successful initial immunotherapy. Nat Med 2007; 13:354-60.
10. + T cells in the absence of tumor-antigen vaccination. Proc Natl Acad Sci USA 2001; 98:10811-6.
11. Bartholdy C, Kauffman SO, Chirstensen JP, Thomsen AR. Agonistic anti-CD40 antibody profoundly suppresses the immune response to infection with lymphcytic choriomeningitis virus. J Immunol 2007; 178:1662-70. (Pubitemid 46154638)
12. Mauri C, Mars LT, Londei M. Therapeutic activity of agonistic monoclonal antibodies against CD40 in a chronic autoimmune inflammatory process. Nat Med 2000; 6:673-9.
13. + T cell memory. Science 2002; 297:2060-3.
14. Bishop GA, Moore CR, Xie P, Stunz LL, Kraus ZJ. TRAF proteins in CD40 signaling. Adv Exp Med Biol 2007; 597:131-51.
15. Loskog ASI, Eliopoulos AG. The Janus faces of CD40 in cancer. Semin Immunol 2009; 21:301-7.